Mineral Oil

Summary

Mineral Oil (CHEMBL2109152) is a phase-3 clinical-stage unknown (ATC A06AA51); indicated across 5 conditions including constipation disorder and otomycosis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• ATC class: A06AA51 (+1 more)
• Indications: 5 conditions
• Clinical trials: 12

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109152
Name	Mineral Oil
Type	Unknown
Max phase	3
ATC	A06AA51, A06AA01

Also known as: Alpha keri, Ashbourne emollient, Aveeno, Dermalo, Doublebase, E-905D, Emmolate, Emulsiderm, Gppe emollient, Heavy liquid petrolatum, INS NO.905D, INS-905D

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
constipation disorder	4	MONDO:0002203	HP:0002019
otomycosis	3	MONDO:0000262	MONDO:0000262
skin disorder	1	MONDO:0005093	EFO:0000701

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 12.

Phase distribution

Phase	Trials
Not specified	6
PHASE3	2
PHASE2	2
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00861952	PHASE3	WITHDRAWN	Neuragen for Peripheral Diabetic Neuropathy
NCT01445431	PHASE3	COMPLETED	A Trial on the Efficacy and Safety of Virgin Coconut Oil Compared to Mineral Oil in the Treatment of Uremic Xerosis
NCT01408407	PHASE2	TERMINATED	Alkagin Paste in the Prevention of Radiation Dermatitis
NCT01701466	PHASE2	TERMINATED	Neoviderm Skin Emulsion in the Prevention of Radiation Dermatitis
NCT02379793	PHASE1	COMPLETED	Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects
NCT06494566	EARLY_PHASE1	COMPLETED	Omega-3 Supplementation After Surgical Treatment of Obesity
NCT06453512	Not specified	RECRUITING	A Study to Evaluate the Emollient Performance of Doublebase Once in the Treatment of Atopic Eczema
NCT02103556	Not specified	COMPLETED	Edible Oils in the Treatment of Constipation of Hemodialysis Patients
NCT03463642	Not specified	COMPLETED	The Efficacy of Different Vitamin D Supplementation Delivery Methods
NCT04585230	Not specified	UNKNOWN	A Study to Evaluate the Outcomes of Cannabinoid (CBD) Roll-on Topical Stick in Primary Total Knee Arthroplasty
NCT05259800	Not specified	TERMINATED	Peppermint Oil for Urinary Retention
NCT06747897	Not specified	COMPLETED	An Observational Study to Gather Real-World User Feedback on DIPROBASE® Advanced Eczema Cream in Adults and Children With Eczema or Dry Skin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).